FDA Warns of Sudden Vision Loss Risk with GLP-1 Medications

FDA Warns of Sudden Vision Loss Risk with GLP-1 Medications5 publishers · first seen Tue, 10 Nov 2026 17:01 UTC · updated Thu, 12 Nov 2026 15:12 UTCThe FDA has issued a warning about the potential risk of sudden vision loss for people taking GLP-1 medications. The FDA is requiring manufacturers to add information about the potential association between these drugs and non-arteritic anterior ischemic optic neuropathy (NAION) to the Warnings and Precautions section of their labels. NAION is a rare condition that can lead to vision loss in one eye, and it can be permanent. The FDA cited studies and its own meta-analyses in the notice. The agency also noted that NAION cases have been reported for all currently marketed GLP-1 products.Content auto-generated. May contain inaccuracies.

Роналду запускає власний серіал: футболіст зіграє самого себе — фото (NV, Thu, 12 Nov 2026 15:12 UTC)

Could Your GLP-1s Make You Blind? Here’s What to Make of the FDA’s Latest Notice. (Latest Content - Men's Health, Thu, 12 Nov 2026 15:06 UTC)

Could Your GLP-1s Make You Blind? Here’s What to Make of the FDA’s Latest Notice. (Women's Health, Thu, 12 Nov 2026 12:00 UTC)

GLP-1 drugs must now carry warning labels about rare risk of vision loss (PhillyVoice, Tue, 10 Nov 2026 21:28 UTC)

FDA warns GLP-1s could increase risk of vision loss (WBUR, Tue, 10 Nov 2026 17:01 UTC)